We next examined whether TMEM44-AS1 was required for the anti-proliferative effect of this Myci975 therapy by treating SF126 and PN16 glioma cells stably expressing TMEM44-AS1 or/ empty vector with Myci975. This evidence concerns the gene PTGDR and central nervous system cancer.